The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.
Drugging the p53 pathway: understanding the route to clinical efficacy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The TP53 gene is inactivated by mutation in about half of all human cancers [1, 3, 4].”
From Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog (2022) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–234 of 234
Li, C., & Johnson, D. E. (2013) · Cell Cycle · doi:10.4161/cc.23882 · Cited by 50
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219142110 · Cited by 49
Zauli, G., Voltan, R., Bosco, R., Melloni, E., Marmiroli, S., Rigolin, G. M., Cuneo, A., & Secchiero, P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2572 · Cited by 49
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy
Azmi, A. S., Philip, P. A., Beck, F. W., Wang, Z., Banerjee, S., Wang, S., Yang, D., Sarkar, F. H., & Mohammad, R. M. (2010) · Oncogene · doi:10.1038/onc.2010.403 · Cited by 48
The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts
Secchiero, P., Zerbinati, C., Melloni, E., Milani, D., Campioni, D., Fadda, R., Tiribelli, M., & Zauli, G. (2007) · Neoplasia · doi:10.1593/neo.07523 · Cited by 48
An Expeditious Synthesis of the MDM2–p53 Inhibitor AM-8553
Lucas, B. S., Fisher, B., McGee, L. R., Olson, S. H., Medina, J. C., & Cheung, E. Y. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305123v · Cited by 47
Ribas, J., Boix, J., & Meijer, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.04.021 · Cited by 45
Rigatti, M. J., Verma, R., Belinsky, G. S., Rosenberg, D. W., & Giardina, C. A. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20795 · Cited by 45
Shen, J., van den Bogaard, E. H. J., Kouwenhoven, E. N., Bykov, V. J. N., Rinne, T., Zhang, Q., Tjabringa, G. S., Gilissen, C., van Heeringen, S. J., Schalkwijk, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201993110 · Cited by 45
Small molecules that bind the Mdm2 RING stabilize and activate p53
Roxburgh, P., Hock, A. K., Dickens, M. P., Mezna, M., Fischer, P. M., & Vousden, K. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs092 · Cited by 43
Secchiero, P., Vaccarezza, M., Gonelli, A., & Zauli, G. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382747 · Cited by 43
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O. (2012) · Cancer · doi:10.1002/cncr.27837 · Cited by 42
Tovar, C., Higgins, B., Kolinsky, K. D., Xia, M., Packman, K. E., Heimbrook, D. C., & Vassilev, L. T. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-49 · Cited by 41
Lane, D. P., & Verma, C. S. (2012) · Genes & Cancer · doi:10.1177/1947601912458285 · Cited by 41
Self-citationMir, R., Tortosa, A., Martínez‐Soler, F., Vidal, A., Condom, E., Pérez‐Perarnau, A., Ruiz‐Larroya, T., Gil, J., & Gimenez‐Bonafé, P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27832 · Cited by 40
A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX
Henry, R. E., Andrysík, Z., París, R., Galbraith, M. D., & Espinosa, J. M. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.498 · Cited by 40
Nakamura, Y., Kato, H., Nishikawa, T., Iwasaki, N., Suwa, Y., Rotinsulu, H., Losung, F., Maarisit, W., Mangindaan, R. E. P., Morioka, H., et al. (2013) · Organic Letters · doi:10.1021/ol3032363 · Cited by 39
ElSawy, K. M., Verma, C. S., Joseph, T. L., Lane, D. P., Twarock, R., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.23511 · Cited by 37
Self-citationCyclotherapy: opening a therapeutic window in cancer treatment
van Leeuwen, I. M. M. (2012) · Oncotarget · doi:10.18632/oncotarget.524 · Cited by 36
Nutlin‐3 enhances sorafenib efficacy in renal cell carcinoma
Vatsyayan, R., Singhal, J., Nagaprashantha, L. D., Awasthi, S., & Singhal, S. S. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20875 · Cited by 34
Thompson, T., Andreeff, M., Studzinski, G. P., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1036 · Cited by 32
Hernychová, L., Man, P., Verma, C. S., Nicholson, J., Sharma, C.-A., Růčková, E., Teo, J. Y., Ball, K. L., Vojtesek, B., & Hupp, T. R. (2013) · PROTEOMICS · doi:10.1002/pmic.201300029 · Cited by 32
Self-citationAdaptive Evolution of p53 Thermodynamic Stability
Khoo, K. H., Andreeva, A., & Fersht, A. R. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.08.013 · Cited by 32
Self-citationBrown, Z. Z., Akula, K., Arzumanyan, A. L., Alleva, J. L., Jackson, M. A., Bichenkov, E., Sheffield, J. B., Feitelson, M. A., & Schafmeister, C. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045948 · Cited by 29
In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
Wei, S. J., Joseph, T. L., Sim, A. Y. L., Yurlova, L., Zolghadr, K., Lane, D. P., Verma, C. S., & Ghadessy, F. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062564 · Cited by 29
Self-citationInhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides
Wei, S. J., Joseph, T. L., Chee, S. M. Q., Li, L., Yurlova, L., Zolghadr, K., Brown, C. J., Lane, D. P., Verma, C. S., & Ghadessy, F. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081068 · Cited by 27
Self-citationStructural insights into the dual-targeting mechanism of Nutlin-3
Shin, J., Ha, J., He, F., Muto, Y., Ryu, K., Yoon, H. S., Kang, S., Park, S. G., Park, B. C., Choi, S., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.02.113 · Cited by 26
Brown, C. J., Dastidar, S. G., Quah, S. T., Lim, A., Chia, B. C. S., & Verma, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024122 · Cited by 26
Self-citationNoguchi, T., Oishi, S., Honda, K., Kondoh, Y., Saito, T., Kubo, T., Kaneda, M., Ohno, H., Osada, H., & Fujii, N. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.094 · Cited by 24
Ma, T., Yamada, S., Ichwan, S. J. A., Iseki, S., Ohtani, K., Otsu, M., & Ikeda, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.161 · Cited by 19
Riedinger, C., Noble, M. E. M., Wright, D. J., Mulks, F. F., Hardcastle, I. R., Endicott, J., & McDonnell, J. M. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01091.x · Cited by 17
Lew, Q. J., Tan, C. H., Gurumurthy, M., Chu, K. L., Cheong, N., Lane, D. P., & Chao, S. (2011) · Cell Cycle · doi:10.4161/cc.10.12.15859 · Cited by 13
Self-citationTumor Suppression by p53 without Accelerated Aging: Just Enough of a Good Thing?
Mendrysa, S. M., & Perry, M. E. (2006) · Cell Cycle · doi:10.4161/cc.5.7.2632 · Cited by 11
Cited by
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D'Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,658
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Metadata
- Authors
- Khoo, K. H., Verma, C. S., & Lane, D. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-02-28
- Volume
- 13
- Issue
- 3
- Pages
- 217-236
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028387032
- Cited by
- 719
- References
- 234
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.